𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

✍ Scribed by Howard H. Bailey; Michelle R. Mahoney; David S. Ettinger; William J. Maples; Paula M. Fracasso; Anne M. Traynor; Charles Erlichman; Scott H. Okuno

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
110 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of cisplatin (CPDD) in pr
Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma
✍ Joseph Brenner; Gordon B. Magill; Peter P. Sordillo; Edgar W. Cheng; Allan Yagod πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 249 KB πŸ‘ 3 views

Thirty-six previously treated adult patients with advanced soft tissue sarcomas received CPDD 120 mg/m2 with mannitol diuresis. There were only two (6%) partial responses and five (15%) minor responses in 34 evaluable patients. Toxicity included nausea and vomiting, myelosuppression, mild ototoxicit

Results of a 2-arm Phase II study of 9-n
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas
✍ Shreyaskumar R. Patel; Jennifer Beach; Nicholas Papadopoulos; M. Andrew Burgess; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 3 views

## Abstract ## BACKGROUND The authors conducted a 2‐arm Phase II trial of 9‐nitrocamptothecin (9‐NC), an oral topoisomerase I inhibitor, to define response rates in patients with gastrointestinal (GI) leiomyosarcomas and other soft‐tissue sarcomas (STS). ## METHODS Patients were required to prov

A two-arm phase II study of temozolomide
A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas
✍ Jonathan C. Trent; Jennifer Beach; Michael A. Burgess; Nicholas Papadopolous; Le πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 141 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The authors conducted a two‐arm Phase II study of temozolomide to determine its efficacy and toxicity in patients with soft tissue sarcomas (STSs) who had received, had refused, or were not eligible for standard chemotherapy with doxorubicin and ifosfamide (Arm 1) and in